OptiScan Biomedical has introduced its OptiScanner 6000, which builds upon the company's current OptiScanner bedside glucose monitoring platform for the intensive care unit.
OptiScanner 6000 automatically measures and trends multiple analytes including glucose, ScvO2 (oxygen in the superior vena cava of the heart), and hemoglobin. The next-generation device, which requires no calibration, provides clinicians with real-time and trending data supporting early detection of changes in the critically ill.
Expanded monitoring capabilities of the device have been designed to support clinical treatment decisions by providing critical care physicians with meaningful information to assess their patients’ metabolic and hemodynamic status.
OptiScan Biomedical chairman and CEO Peter Rule noted the company’s goal in developing the new OptiScanner 6000 is to provide critical care physicians a single automated product that meets their most important real-time patient monitoring needs.
"We believe the product represents a true breakthrough as it offers highly accurate monitoring of multiple key analytes in the same, small sample of blood without requiring any calibration or a dedicated catheter.
"Critical care doctors are responsible for treating multiple patients with varying life-threatening conditions all at the same time. The more a platform like the OptiScanner can enhance their ability to make rapid yet informed treatment decisions based on real-time and trending data, the better equipped they will be to deliver optimal patient outcomes," Rule added.
The company has presented the latest clinical data from its ongoing MANAGE II Study (Manual vs. Automated moNitoring Accuracy of GlucosE) in 93 patients. The blinded study showed the difficulties related to the management of blood glucose levels in the critical care setting.
Findings in the study showed that a significant portion of patients in the critical care unit experienced high blood sugar or hyperglycemia.
OptiScan will initiate a US-based pivotal trial with the OptiScanner 5000 based on the positive results from the MANAGE I and MANAGE II studies for continuous blood glucose monitoring in the near future.
OptiScan Biomedical introduced the OptiScanner as part of a special symposium at the 34th International Symposium on Intensive Care and Emergency Medicine being held this week in Brussels, Belgium.